Skip to main content
logo
Immunome, Inc. (IMNM)
NASDAQ: IMNM · Real-Time Price · USD
28.75
-0.64 (-2.18%)
At close: Aug 26, 2026, 4:00 PM EDT
28.50
-0.25 (-0.87%)
Pre-market: Aug 27, 2026, 5:35 AM EDT

Immunome Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
-6.949.0414.02--
Revenue Growth
--23.23%-35.50%---
Cost of Revenue
206.23177.29129.5423.0923.11-
Gross Profit
-206.23-170.35-120.5-9.07-23.11-
Selling, General & Admin
54.2443.7732.9619.6613.7911.09
Research & Development
-----14.11
Operating Expenses
54.2443.7732.9619.6613.7925.2
Operating Income
-260.47-214.11-153.46-28.73-36.9-25.2
Interest Expense
------0.01
Interest & Investment Income
16.1411.7212.842.720.01-
EBT Excluding Unusual Items
-244.32-202.39-140.62-26-36.9-25.21
Other Unusual Items
-----0.5
Pretax Income
-254.32-212.39-292.96-106.81-36.9-24.71
Net Income
-254.32-212.39-292.96-106.81-36.9-24.71
Preferred Dividends & Other Adjustments
----0.62-
Net Income to Common
-254.32-212.39-292.96-106.81-37.52-24.71
Net Income Growth
------
Shares Outstanding (Basic)
1028759201212
Shares Outstanding (Diluted)
1028759201212
Shares Change
41.38%48.96%195.51%63.64%5.10%240.41%
EPS (Basic)
-2.49-2.43-5.00-5.38-3.09-2.14
EPS (Diluted)
-2.49-2.43-5.00-5.38-3.09-2.14
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-219.09-200.6-117.97-8.4-28.94-18.31
Free Cash Flow Per Share
-2.14-2.30-2.01-0.42-2.39-1.59
Gross Margin
----64.71%--
Operating Margin
--3084.76%-1697.33%-204.94%--
Profit Margin
--3059.99%-3240.38%-761.92%--
Free Cash Flow Margin
--2890.13%-1304.80%-59.92%--
EBITDA
-257.69-211.65-151.89-28.27-36.48-24.45
EBITDA Margin
----201.68%--
D&A For EBITDA
2.782.471.570.460.420.76
EBIT
-260.47-214.11-153.46-28.73-36.9-25.2
EBIT Margin
----204.94%--
SEC Filings: 10-K · 10-Q